Journal Detail Information

1

Cite

Share

Malignant Fibrous Histiocytoma of the Lung.

Jung Joo HWANG ; Doo Yun LEE ; Eun Kyu JOUNG ; Sc Eun JEON ; Jung Soo CHO ; Tae Hoon KIM ; San Ho CHO

Journal of Lung Cancer.2005;4(2):115-118.

Malignant fibrous histiocytoma (MFH) is a primitive sarcoma originating in the deep soft tissue and composed of fibrocytic and histiocytic cells in a storiform pattern. It is rare but the most common soft tissue sarcoma of adulthood. MFH occurred in various epithelial organs derived from the supportive mesenchymal elements. The lung represents an extremely rare primary site. We have experienced one case of MFH, arising in the lung parenchyme in 67 years old male patient with cough for 6 months. The patient was taken right upper lobe and right middle lobe lobectomy with good post-operative results. But another MFH was recurred in the left upper lobe 3 months after complete resection. So he had been treated with chemotherapy and radiofrequency ablation of tumor. Then he continued to be treated with chemotherapy
Aged ; Catheter Ablation ; Cough ; Drug Therapy ; Histiocytoma, Malignant Fibrous* ; Humans ; Lung* ; Male ; Sarcoma

2

Cite

Share

Glut1 Expression and FDG Uptake in Non-small Cell Lung Carcinoma: Its Relationship to Histopathologic Types and Proliferation Rate.

Suk Ki CHO ; Kyong Min RYU ; Hyun Joo LEE ; Jin Haeng CHUNG ; Won Woo LEE ; Sang Hoon JHEON ; Sook Whan SUNG

Journal of Lung Cancer.2005;4(2):107-114.

PURPOSE: 18F-fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography (PET) is known to be useful in the detection of lung cancer. However, the degree of FDG uptake was variable. To correlate FDG activity on PET with various histopathologic factors,we assessed the relationships between 18F-FDG uptake and glucose transporter 1 (Glut1) expression, histologic subtypesand Ki-67 labelling indices. MATERIALS AND METHODS: One hundred two patients with non-small cell lung cancer (NSCLC) who had surgery and preoperative 18F-FDG PET scan as a part of the staging work-up were enrolled in this study. The amount of FDG uptake in the primary lesion was measured by a standardized uptake values (SUVs) and correlated with tumor size, histologic subtypes, and immunohistochemical results of Glut1 and Ki-67 labelling indices. RESULTS: Cell type of NSCLC were 52 adenocarcinomas, 36 squamous cell carcinomas, 14 other NSCLC. All tumors could be detected by FDG PET. Uptake was correlated with tumor size (p<0.01). The FDG uptake was significantly lower in adenocarcinomas than in squamous cell carcinomas or other NSCLC (p<0.001). The percentages of Glut1- positive area and staining intensity of the tumor were also significantly lower in adenocarcinomas than in squamous cell carcinomas or other NSCLC (p<0.001). Ki-67 labelling indices of the tumor correlated with the percentage of Glut1 intensity and SUVs in NSCLC (p7lt;0.001). CONCLUSION: These results suggest that overexpression of Glut1 and proliferating activity is related to 18F-FDG uptake in NSCLC. Glut1 expression appear to be different among histologic subtypes. Glut1 expression, as well as FDG uptake, is lower in adenocarcinomas than squamous cell carcinomas or other NSCLC.
Adenocarcinoma ; Carcinoma, Non-Small-Cell Lung ; Carcinoma, Squamous Cell ; Fluorodeoxyglucose F18 ; Glucose Transport Proteins, Facilitative ; Humans ; Lung Neoplasms ; Lung* ; Positron-Emission Tomography

3

Cite

Share

The Effects of Photodynamic Therapy with Photogem and Laser with Power Density of 600 mW/cm2 on Lewis Lung Carcinoma Cells Tumor Graft in Mouse.

Sun Jung KWON ; Ju Ock KIM ; Jin Yong AN ; Sung Soo JUNG ; Hyun Soo LIM ; Kyu Sang SONG ; Young Ha LEE ; Sun Young KIM

Journal of Lung Cancer.2005;4(2):101-106.

PURPOSE: Photodynamic therapy was used to lung cancer. We have made a light microscpic study on the effects of photodynamic therapy to tumor graft in skin of mice, when the power density was 600 mW/cm2 with reducing time. MATERIALS AND METHODS: These studies had been performed on sixteen C57BL/6 mice that Lewis lung carcinoma cells had been implanted. All mice were divided into four groups. One of four groups received Photogem 3 mg/kg intravenously 24 hours prior to exposure of tumor to 180 J/cm2 laser light vertically at a wavelength 635etam with a higher power density of 600 mW/cm2 than that of 400 mW/cm2 clinically. One of these group received only Photogem. The others not received Photogem and one of these irradiated with laser. The light source was the wavelength of 635 etam Diode Laser (Laxcell 2004, Bio- Optics. co. Korea) After photodynamic therapy was finished, staining and analysing of tumors were used to determine the natures and extents of injury. RESULTS: Grossly response was not observed. Histologically, there were loss of endothelium from small vessel at tumor and muscle with thrombus formation. There were focal necrosis with infiltration of inflammatory cells at tumor and adjacent tissues that irradiated with laser, regardless of administration of Photogem. CONCLUSION: Photodynamic therapy using Photogem and LASER with power density of 600 mW/cm2 destroy not only tumors incompletely but also adjacent normal tissue.
Animals ; Carcinoma, Lewis Lung* ; Endothelium ; Lasers, Semiconductor ; Lung Neoplasms ; Mice* ; Necrosis ; Photochemotherapy* ; Skin ; Thrombosis ; Transplants*

4

Cite

Share

Effect of Postoperative Pulmonary Morbidities on the Survival in Patients with Non-small Cell Lung Cancer.

Suk Won SONG ; Hyun Sung LEE ; Moon Soo KIM ; Jong Mog LEE ; Jae Hyun KIM ; Jae Ill ZO

Journal of Lung Cancer.2005;4(2):94-100.

PURPOSE: The purpose of this study was to identify the effect postoperative pulmonary complications (PPCs) in patients with non-small cell lung cancer undergoing pulmonary resection on survival. MATERIALS AND METHODS: The study involved a retrospective review of 635 patients over a 4-year period who had undergone curative lung resection for non-small cell lung cancer. The patient group included 504 (79.4%) males, and the overall mean age was 61.3 years. Patients were classified as those who had experienced PPCs (PPCs group, n=105, 16.5% of all patients) or those who had not (no PPCs group, n=530 patients). RESULTS: The surgical procedures performed were 101 (15.9%) pneumonectomies, 505 (79.5%) lobectomies and 29 (4.6%) lesser resections. Cancer types comprised 330 (52.0%) squamous cell carcinomas, 255 (40.2%) adenocarcinomas and 50 (7.8%) others. Overall survival 3 years after surgery was 68.2% in the no PPCs group and 38.8% in the PPCs group (p<0.0001). Regardless of tumor staging, overall survival differed significantly between the PPCs and no PPCs groups, while disese-free survival did not. Seventy-six patients (14.9%) in the no PPCs group and 24 patients (27.3%) in the PPCs group died during the follow up period. The primary cause of death was the recurrence of the primary lung cancer in both groups (68 patients in the no PPCs and 14 in the PPCs). The second most frequent cause of deaths was respiratory failure in the PPCs group (9 patients : 10.2%). Respiratory failure was less observed in the no PPCs group. In contrast, the incidence of respiratory failure leading to death constantly increased in the PPCs group. CONCLUSION: Patients who had postoperative pulmonary complications have taken the risk of poor survival. We emphasize on the fact that patients who experienced postoperative pulmonary complications need careful and frequent shortterm follow-up to improve overall survival
Adenocarcinoma ; Carcinoma, Non-Small-Cell Lung* ; Carcinoma, Squamous Cell ; Cause of Death ; Follow-Up Studies ; Humans ; Incidence ; Lung ; Lung Neoplasms ; Male ; Neoplasm Staging ; Pneumonectomy ; Recurrence ; Respiratory Insufficiency ; Retrospective Studies

5

Cite

Share

The Evaluation of Postoperative Acute Respiratory Failure in Primary Lung Cancer with Interstitial Pneumonia.

Jae Kil PARK ; Young Jo SA ; Young Pil WANG

Journal of Lung Cancer.2005;4(2):89-93.

PURPOSE: Since acute respiratory failure was one of the most fatal postoperative complications in lung cancer surgery, to know its incidence, and predisposing factors is very important. The purpose of this study was to determine the relationship between pre-operative interstitial pneumonia (IP) and post-operative acute respiratory failure. MATERIALS AND METHODS: A retrospective review of 672 patients with lung cancer who underwent curative pulmonary resection at the Hospital of Catholic University Medical College between 1997 and 2005 was undertaken. The patients were divided into two groups according to preexisting interstitial pneumonia or not by pre-operative chest HRCT or findings of pathologic papers. RESULTS: Twenty-eight patients (4.2%) developed post- operative respiratory failure and this proved to be fatal in 21 of these patients. We could find preoperative interstitial pathology in 53 patients (7.9%) among the 672 patients. The incidences of respiratory failure were 11.3% (6/53 cases) and 3.6% (22/619 cases) in IP group and non-IP group respectively. CONCLUSION: Interstitial pneumonia considered of one of the risk factors for developing postoperative acute respiratory failure in patients with lung cancer.
Causality ; Humans ; Incidence ; Lung Diseases, Interstitial* ; Lung Neoplasms* ; Lung* ; Pathology ; Postoperative Complications ; Respiratory Insufficiency* ; Retrospective Studies ; Risk Factors ; Thorax

6

Cite

Share

Multimodality Treatment Based on Induction Chemotherapy for Stage III NSCLC.

Yeun Seun LEE ; Pil Soon JANG ; Hyun Mo KANG ; Jeung Eyeun LEE ; Ju Moon JO ; Pyeung Seung LIM ; Sung Soo JUNG ; Ju Ock KIM ; Sun Young KIM

Journal of Lung Cancer.2005;4(2):81-88.

PURPOSE : The aim of this study was to validate the effect and the feasibility of induction chemotherapy in patients with locally advanced non-small cell lung cancer (NSCLC) on multimodality treatment. MATERIALS AND METHODS : From January 2002 to December 2003, 84 chemonaive patients with Stage III NSCLC, median age of 64 years, ECOG perfomance satus 0, 1, or 2, and without other comorbid disease were enrolled this study and received chemotherapy every 3 weeks. After two or three cycles of induction chemotherapy (gemcitabine with cisplatin), patients were reevaluated by chest CT and then underwent resection, radiotherapy, further chemotherapy, or observation. RESULTS : Overall clinical responses were seen in 43 (57%) of the 76 assessable patients. Response rates were 61% and 53% in patients with stage IIIA and IIIB disease, respectively. Twenty-eight patients out of initially unresectable 70 patients (19 of 32 stage IIIA and 9 of 38 stage IIIB) after induction chemotherapy seemed to be resectable. Operation was done in 23 out of 32 patients who achieved clinically resectable stage after induction chemotherapy and 20 (87%) resections were complete and 3 were incomplete including 1 case of open & closure. Thirty-two patients were treated with chest radiation after chemotherapy. Eighteen patients were treated with chemotherapy upto 6 cycles and 6 patients refused further treatment after induction chemotherapy. Median follow up of all patients was 16.2 months, median survival was 16 months, and estimated disease progression free interval was 11 months. Survival and disease progression free interval were different with between induction chemotherapy followed by complete resection subgroup and followed by radiation therapy subgroup (24 vs. 14 months, p=0.04). Grade 3/4 neutropenia and thrombocytopeina were noticed in 29% and 10%, respectively and one chemotherpy related death was also noticed. CONCLUSION : Induction chemotherapy followed by surgery with or without adjuvant radiation might be the recommendable management to improve the survival in locally advanced NSCLC with feasible toxicity
Carcinoma, Non-Small-Cell Lung ; Disease Progression ; Drug Therapy ; Follow-Up Studies ; Humans ; Induction Chemotherapy* ; Neutropenia ; Radiotherapy ; Thorax ; Tomography, X-Ray Computed

7

Cite

Share

Three-Weekly Gemcitabine Plus Cisplatin Chemotherapy in Patients with Locally Advanced or Metastatic Non-small-cell Lung Cancer: Phase II Study of the Korean Association for the Study of Lung Cancer.

Jeong Seon RYU ; Maan Hong JUNG ; Sun Young KIM ; Se Kyu KIM ; Young Chul KIM ; Eun Taik JUNG

Journal of Lung Cancer.2005;4(2):74-80.

PURPOSE: As one of the new chemotherapeutic agents, gemcitabine is widely used as a four-week schedule in combination with cisplatin in the treatment of advanced non-small-cell lung cancer (NSCLC). In this study, we evaluated the efficacy, tolerance, and survival effect of this combination in a three-week schedule in patients with locally advanced inoperable or metastatic NSCLC. MATERIALS AND METHODS: Between January 2000 and September 2002, previously untreated 124 NSCLC patients were enrolled and 118 patients, who completed at least two cycles of chemotherapy, were evaluated. Patients received gemcitabine 1200 mg/m2 on days 1 and 8, cisplatin 75 mg/m2 on day 1 of a 21-day cycle, for a maximum of 6 cycles. RESULTS: They were 81 men and 37 women. Clinical stage IIIB was present in 56 (47.5%), and stage IV in 62 (52.4%) patients. Sixty-seven patients (56.8%) had a performance status of ECOG grade 0 or 1 and fifty-one patients (43.2%) of grade 2. During the period of chemotherapy, grade 3/4 leukopenia and neutropenia were observed in 19.5% and 31.4%, respectively and grade 3/4 thrombocytopenia in 7.6%. The overall response rate was 52.5% among the 118 patients. Overall median survival time was 12.2 months, and one-year and two-year survival rates were 50.2% and 20.4% respectively. The presence of response to chemotherapy, ECOG performance status of grade 0~1, and women showed better survival by the univariate analysis (p=0.010, 0.001 and 0.015, respectively). CONCLUSION: A three weekly gemcitabine/cisplatin doublet was relatively well tolerated, with an acceptable response rate and a reasonable median survival in locally advanced inoperable or metastatic NSCLC.
Appointments and Schedules ; Cisplatin* ; Drug Therapy* ; Female ; Humans ; Leukopenia ; Lung Neoplasms* ; Lung* ; Male ; Neutropenia ; Survival Rate ; Thrombocytopenia

8

Cite

Share

EGFR Tyrosine Kinase Inhibitors for NSCLC.

Young Chul KIM

Journal of Lung Cancer.2005;4(2):71-73.

The EGFR Tyrosine kinase inhibitors (TKIs) show significant clinical benefit in selected population with no smoking history, adenocarcinoma or mutations in EGFR gene. Mutations of K-ras gene are associated with resistance to EGFR TKIs. Three published studies of gefitinib experience from Korea are reviewed. Mutations of EGFR gene published up to now and correlation with response to EGFR-TKIs is summarized. This review also discusses the suggested mechanisms of acquired resistance to EGFR TKIs
Adenocarcinoma ; Genes, erbB-1 ; Genes, ras ; Korea ; Protein-Tyrosine Kinases* ; Smoke ; Smoking ; Tyrosine*

9

Cite

Share

Small Cell Lung Cancer at Subcarina Presenting as a Metastatic Brain Tumor.

Mi Ae KIM ; Eun Kyung KIM ; Ji Hyun LEE ; Hye Cheol JEONG

Journal of Lung Cancer.2010;9(1):24-25. doi:10.6058/jlc.2010.9.1.24

A 59-year-old man was rushed to the emergency room. The patient complained of headache with impaired memory function. Brain MRI showed a necrotic tumor in Lt cerebral hemisphere, with severe peritumoral edema (Fig. 1). Pathologic examination of the brain lesion confirmed that the tumor was a small cell lung cancer (SCLC). Chest computed tomography revealed a large soft tissue mass with central necrosis at subcarinal area in spite of an initial normal chest X-ray (Fig. 2). Bronchoscopic biopsy of the polypoid mass at subcarina revealed that the mass was a SCLC (Fig. 3). This is the case of SCLC only with an extrapulmonary symptoms despite of a normal chest X-ray. When metastatic brain tumor was found, appropriate chest evaluation should be performed even though chest X-ray was normal because brain is a common site of invasion of lung cancer.
Biopsy ; Brain ; Brain Neoplasms ; Cerebrum ; Edema ; Emergencies ; Headache ; Humans ; Lung Neoplasms ; Memory ; Middle Aged ; Necrosis ; Small Cell Lung Carcinoma ; Thorax

10

Cite

Share

Primary Acinic Cell Carcinoma of the Lung: A Case Report.

Junhun CHO ; Taeeun KIM ; Joungho HAN ; Kwhanmien KIM ; Tae Sung KIM

Journal of Lung Cancer.2010;9(1):20-23. doi:10.6058/jlc.2010.9.1.20

Primary acinic cell carcinoma (ACC) of the lung is very rare and this tumor is thought to arise from pluripotent cells of the submucosal glands of the tracheobronchial tree. We report here on a case of primary ACC of the lung in a 68-year-old man who had a solitary pulmonary nodule in the left lower lobe. The patient was symptomless and the lesion was found on a chest X-ray taken during a regular health checkup. The video assisted thoracoscopic surgery wedge resection revealed an ovoid yellow tan solid mass that was 1.8 cm at the largest diameter. Microscopically, the neoplastic cells grew in solid sheets of round cells with eccentric nuclei and abundant basophilic granular cytoplasm. There were no mitotic figures or areas of pleomorphic or anaplastic cells. Immunohistochemical staining for cytokeratin (AE1/AE3) was positive, but the staining for chromogranin A and CD56 was negative. Ultrastructural examination revealed polyhedral cells with many zymogen granules of varying electron density. The patient is well 4 months postoperatively.
Acinar Cells ; Aged ; Basophils ; Carcinoma, Acinar Cell ; Chromogranin A ; Cytoplasm ; Electrons ; Humans ; Keratins ; Lung ; Lung Neoplasms ; Secretory Vesicles ; Solitary Pulmonary Nodule ; Thoracic Surgery, Video-Assisted ; Thorax ; Triacetoneamine-N-Oxyl

DISPLAY OPTIONS

Cite

Share

Cite

Share

Cite

Share

Cite

Share

Cite

Share

Cite

Share

Cite

Share

Cite

Share

Cite

Share

Cite

Share